IgA Tarpeyo denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for iga tarpeyo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Imposes Quantity Limits on Tarpeyo — and How to Appeal When They Don't Fit Your Case

UnitedHealthcare applies quantity limits to Tarpeyo (budesonide delayed-release capsules for IgA nephropathy) as part of its standard specialty drug management. A quantity-limit denial means the plan will only cover the drug up to a defined supply amount per dispensing period, and your prescription exceeds that limit. This can occur when a prescriber writes for a supply that reflects the full treatment course defined in the FDA-approved prescribing label, while the plan's limit reflects a shorter interval or lower quantity.

Quantity limits on Tarpeyo are particularly worth appealing because the approved treatment course has a defined duration and regimen. If the prescribed quantity aligns with the FDA-approved prescribing information and your nephrologist's clinical judgment, the limit creates a barrier to completing a course of therapy as medically directed.

## Your Federal Appeal Rights

• ACA §2719 / ERISA §503: A quantity-limit denial is an adverse benefit determination. You are entitled to internal appeal and, for non-grandfathered plans, binding external review by an IRO.
• Quantity-limit exception process: Many plans have a quantity-limit exception process separate from the PA pathway. Ask whether submitting a quantity exception request is available in addition to or instead of a standard internal appeal.
• Timeline: Internal appeal generally within 180 days of the denial notice. External review for approximately four months after exhausting internal remedies. Use expedited review if your clinical situation makes delay harmful.

## Documentation to Gather Before You Appeal

1. FDA-approved prescribing label — the label specifies the approved dosing regimen and treatment duration. If the prescribed quantity aligns with the labeled course, attach the relevant section and highlight the prescribing instructions. 2. Prescriber letter — your nephrologist should explain why the prescribed quantity is clinically necessary and consistent with the FDA label, and why the plan's quantity limit prevents completion of medically appropriate therapy. 3. Diagnosis and disease-severity documentation — nephrology notes and laboratory data confirming the diagnosis and clinical status. 4. UHC quantity limit policy — request the specific quantity limit in writing and confirm whether an exception process exists. 5. Prior dispensing history — if you have previously received Tarpeyo under this or another plan, records of prior dispensing may support the clinical rationale for the full quantity.

## Criteria-Mapping Structure

Your appeal letter should anchor on the FDA prescribing label: quote the labeled treatment regimen and show that the prescribed quantity is consistent with completing that regimen. Then address each of UHC's stated reasons for the quantity limit. If the limit is based on a plan policy that predates or conflicts with the FDA label, note that directly. Request either a full quantity exception or approval for the quantity needed to complete one full treatment course as labeled.